Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.

Specific research contents: To study the characteristics of glucose and lipid metabolism and fat distribution in overweight/obesity patients with type 2 diabetes mellitus; liraglutide/ semaglutide/ metformin will be applied to patients for one year, and the changes of lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes and the differences among the three groups will be analyzed before and after treatment. The metabolomic changes of overweight/obese patients with type 2 diabetes before and after medication and the differences among the three groups will be analyzed. Explore the correlation between visceral fat content, glucose and lipid metabolism, inflammatory factors and other biochemical indicators and metabolomics.

Inclusion Criteria:

• Aged 18-65 years old
• BMI≥24kg/㎡, or waist circumference: > 85cm (for male) or > 80cm (for female)
• Has been diagnosed with type 2 diabetes mellitus
• Good blood glucose control in recent three months: random blood sugar < 14mmol/L and HbA1c 6-9%
• Not received any drugs affecting glucose and lipid metabolism or weight loss surgery in the past one month

Exclusion Criteria:

• Abnormal weight gain caused by other endocrine diseases
• Severe metabolic diseases, such as diabetic ketoacidosis, hypertonic hyperglycemia
• Type 1 diabetes or other special types of diabetes
• Used drugs affecting glycolipid metabolism in the past three months
• Severe bleeding tendency that unable to complete venous blood collection
• Patients with MRI contraindications
• Severe renal insufficiency or severe liver insufficiency
• Patients with advanced malignant tumors
• Serious cardiovascular and cerebrovascular diseases
• Rheumatic and immune diseases
• Pregnant and lactating women